November 16, 2016 - By Clifton Ray · 0 Comments
Careside Inc (NASDAQ:CASI) institutional sentiment increased to 2 in 2016 Q2. Its up 0.57, from 1.43 in 2016Q1. The ratio is better, as 8 hedge funds opened new and increased holdings, while 4 sold and trimmed stock positions in Careside Inc. The hedge funds in our partner’s database now possess: 2.18 million shares, up from 2.15 million shares in 2016Q1. Also, the number of hedge funds holding Careside Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 5 New Position: 3.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $86.10 million. The Firm is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It currently has negative earnings. It operates through the development of targeted therapeutics for the treatment of cancer segment.
The stock increased 11.27% or $0.17 on November 15, hitting $1.65. CASI Pharmaceuticals Inc (NASDAQ:CASI) has risen 22.22% since April 14, 2016 and is uptrending. It has outperformed by 17.54% the S&P500.
According to Zacks Investment Research, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.”
Wellington Shields & Co. Llc holds 0.36% of its portfolio in CASI Pharmaceuticals Inc for 489,327 shares. Wellington Shields Capital Management Llc owns 561,408 shares or 0.11% of their US portfolio. Moreover, Moors & Cabot Inc. has 0.02% invested in the company for 84,609 shares. The Connecticut-based Manatuck Hill Partners Llc has invested 0.01% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 523 shares.#img1#
Ratings analysis reveals 100% of CASI Pharmaceuticals Inc’s analysts are positive. Out of 2 Wall Street analysts rating CASI Pharmaceuticals Inc, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3 while the high is $4. The stock’s average target of $3.50 is 112.12% above today’s ($1.65) share price. CASI was included in 2 notes of analysts from October 29, 2015. On Thursday, September 22 the stock rating was initiated by Maxim Group with “Buy”. The company was initiated on Thursday, October 29 by H.C. Wainwright.
CASI Pharmaceuticals, Inc., incorporated on September 18, 1991, is a biopharmaceutical company. The Firm is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. The Firm operates through the development of targeted therapeutics primarily for the treatment of cancer segment. The Company’s product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, the United States Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc., and early-stage candidates in preclinical development. The Company’s pipeline also includes 2ME2 (2-methoxyestradial). The Company’s primary research and development focuses on oncology therapeutics.
More recent CASI Pharmaceuticals Inc (NASDAQ:CASI) news were published by: Prnewswire.com which released: “CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In …” on August 16, 2016. Also Prnewswire.com published the news titled: “CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results” on November 14, 2016. Prnewswire.com‘s news article titled: “CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical …” with publication date: May 12, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray